Glaukos Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Glaukos Corporation's estimated annual revenue is currently $294M per year.
- Glaukos Corporation's estimated revenue per employee is $308,176
- Glaukos Corporation's current valuation is $2.5B. (January 2022)
Employee Data
- Glaukos Corporation has 954 Employees.
- Glaukos Corporation grew their employee count by 8% last year.
Glaukos Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | General Manager and VP R&D | Reveal Email/Phone |
2 | Sr. VP, Global Operations | Reveal Email/Phone |
3 | CFO, SVP, Corporate Development | Reveal Email/Phone |
4 | VP | Reveal Email/Phone |
5 | Global VP Market Access | Reveal Email/Phone |
6 | VP, Franchise Head - Glaucoma | Reveal Email/Phone |
7 | VP Product Development | Reveal Email/Phone |
8 | VP Quality Assurance | Reveal Email/Phone |
9 | EVP, Global Commercial Operations | Reveal Email/Phone |
10 | VP, Global Commercial Development | Reveal Email/Phone |
Glaukos Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Glaukos Corporation?
Glaukos Corporation is committed to transforming glaucoma therapy. To this end, Glaukos is bypassing anatomical impediments and treatment conventions to develop treatments that restore natural physiologic outflow as a foundation of significant, steady and sustained glaucoma management. Today, we are at the beginning with an innovative micro technology. In collaboration with our clinician partners, we are building technology towards a safer and more effective treatment for preserving vision in patients with primary open-angle glaucoma.
keywords:N/A
N/A
Total Funding
954
Number of Employees
$294M
Revenue (est)
8%
Employee Growth %
$2.5B
Valuation
N/A
Accelerator
Glaukos Corporation News
Carl Zeiss Meditec AG, Glaukos Corporation, Abbott Laboratories, Alcon ASICO, Ziemer Ophthalmic Systems AG, Katalyst Surgical,...
BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for...
--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for...
Glaukos received pre-market approval for the iStent from the FDA back in 2012 – the first of its kind to do so in the United States, and according to the company’s website, this is actuall the smallest device to be approved by the FDA thus far. Glaucoma is the second leading cause of blindness ...
Laguna Hills-based Glaukos, which is developing a medical device for treating glaucoma, said this week that it has raised $30M in a funding round. The Series F funding was led by Meritech Capital Partners, and also included Versant Ventures, Domain Associates, Montreux Equity Partners, InterWest ...